Accession Therapeutics Limited, a biopharmaceutical company developing next generation cancer immunotherapies, today announced it has dosed the first patient in its Phase I clinical trial evaluating ...

Flashpoint Therapeutics, a biotechnology company pioneering a new class of structural nanomedicine, announced today the publication of foundational research demonstrating the power of its proprietary ...

Pfizer is launching the first clinical trials for its PD-1xVEGF drug, while Akeso detailed the first overall survival win for ...

One person’s side effect could be another person’s treatment if we expand our perspective on small molecule drug targets, ...

Scientists have known that obesity and metabolic dysfunction can make cancers more aggressive. Tumors thrive in bodies ...

GLP-1 drugs such as Ozempic and Wegovy may extend the lives of colon cancer patients, according to a major UC San Diego study ...

A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor ...

The U.S. Food and Drug Administration has granted Fast Track Designation to a new drug combination for metastatic colorectal ...

Pharma companies are spending billions on a treatment based off old drugs, with little evidence it will extend lives.

According to the NCCN Guidelines for metastatic lung cancer, standard therapies remain valuable, but they are no longer sufficient on their own. This is why molecular profiling, targeted therapy, and ...

The HARMONi-A study is the first Phase III trial of an immunotherapy for EGFR-TKI-resistant, EGFR-mutated non-squamous NSCLC to show statistically significant and clinically meaningful improvements in ...